Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development

Jeremie Vitte; Fuying Gao; Giovanni Coppola; Alexander R. Judkins; Marco Giovannini

doi:10.1038/s41467-017-00346-5

Nature Communications (Aug 2017)

Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development

Jeremie Vitte,
Fuying Gao,
Giovanni Coppola,
Alexander R. Judkins,
Marco Giovannini

Affiliations

Jeremie Vitte: Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center (JCCC), University of California Los Angeles
Fuying Gao: Semel Institute for Neuroscience & Human Behavior and Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles
Giovanni Coppola: Semel Institute for Neuroscience & Human Behavior and Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles
Alexander R. Judkins: Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California
Marco Giovannini: Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center (JCCC), University of California Los Angeles

DOI: https://doi.org/10.1038/s41467-017-00346-5
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 13

Abstract

Read online

SMARCB1 mutations predispose to rhabdoid tumors and schwannomas but the mechanisms underlying the tumor type specificity are unknown. Here the authors present new mouse models and show that early Smarcb1 loss causes rhabdoid tumors whereas loss at later stages combined with Nf2 gene inactivation causes shwannomas.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal